L3VLUP
ProSign in

HROW in the 13F filings

Harrow Health Inc · CUSIP 415858109

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q4 2024Q1 2023Q4 2022Q3 2022Q2 2022Q4 2021Q3 2021Q2 2021Q4 2019Q2 2019
Quarter end
31 Mar 2023
the date the book describes
Filed
11 May 2023
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2022 and Q1 2023; 1 listed it in both
Shares listed
369,662
combined, among listed positions
Reported value
$7.8m
combined, at the quarter end

Managers listing HROW in Q1 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Acadian Asset Management LLC369,662$7.8munder 0.1%Trimmed-143,16211 May 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2022 to Q1 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
1 in Q3 2021 to 1 in Q2 2026

Tracked managers listing it, at least.

00111Q2 2019Q4 2019Q2 2021Q3 2021Q4 2021Q2 2022Q3 2022Q4 2022Q1 2023Q4 2024Q2 2026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
HROW by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20191$4.9mn.a.n.a.
Q4 20191$5.0mn.a.n.a.
Q2 20211$4.5mn.a.n.a.
Q3 20211$4.8mn.a.n.a.
Q4 20211$4.6mn.a.n.a.
Q2 20221$4.0mn.a.n.a.
Q3 20221$6.6mn.a.n.a.
Q4 20221$7.6mn.a.n.a.
Q1 20231$7.8mn.a.n.a.
Q4 20241$390kn.a.n.a.
Q2 20261$14m154

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

HROW and LLY →HROW and JNJ →HROW and VRTX →Choose a stock to compare with HROW →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own HROW, latest filings →Back to the 13F Explorer →